Please login to the form below

Not currently logged in
Email:
Password:

enzastaurin

This page shows the latest enzastaurin news and features for those working in and with pharma, biotech and healthcare.

Lilly/Boehringer's empagliflozin faces US approval delay

Lilly/Boehringer's empagliflozin faces US approval delay

last year it suffered late-stage setbacks with antidepressant edivoxetine, enzastaurin for lymphoma and tabalumab for rheumatoid arthritis.

Latest news

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health®

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...